1. |
陈万青, 孙可欣, 郑荣寿, 等. 2014 年中国分地区恶性肿瘤发病和死亡分析. 中国肿瘤, 2018, 27(1): 1-14.
|
2. |
Clark T, Maximin S, Meier J, et al. Hepatocellular carcinoma: review of epidemiology, screening, imaging diagnosis, response assessment, and treatment. Curr Probl Diagn Radiol, 2015, 44(6): 479-486.
|
3. |
Zhao H, Chen Q, Alam A, et al. The role of osteopontin in the progression of solid organ tumour. Cell Death Dis, 2018, 9(3): 356.
|
4. |
Zhang H, Ye QH, Ren N, et al. The prognostic significance of preoperative plasma levels of osteopontin in patients with hepatocellular carcinoma. J Cancer Res Clin Oncol, 2006, 132(11): 709-717.
|
5. |
Xie H, Song J, Du R, et al. Prognostic significance of osteopontin in hepatitis B virus-related hepatocellular carcinoma. Dig Liver Dis, 2007, 39(2): 167-172.
|
6. |
Korita PV, Wakai T, Shirai Y, et al. Overexpression of osteopontin independently correlates with vascular invasion and poor prognosis in patients with hepatocellular carcinoma. Hum Pathol, 2008, 39(12): 1777-1783.
|
7. |
Yang GH, Fan J, Xu Y, et al. Osteopontin combined with CD44, a novel prognostic biomarker for patients with hepatocellular carcinoma undergoing curative resection. Oncologist, 2008, 13(11): 1155-1165.
|
8. |
Kim JY, Bae BN, Kim KS, et al. Osteopontin, CD44, and NFkappaB expression in gastric adenocarcinoma. Cancer Res Treat, 2009, 41(1): 29-35.
|
9. |
Pan HW, Ou YH, Peng SY, et al. Overexpression of osteopontin is associated with intrahepatic metastasis, early recurrence, and poorer prognosis of surgically resected hepatocellular carcinoma. Cancer, 2003, 98(1): 119-127.
|
10. |
Sieghart W, Wang X, Schmid K, et al. Osteopontin expression predicts overall survival after liver transplantation for hepatocellular carcinoma in patients beyond the Milan criteria. J Hepatol, 2011, 54(1): 89-97.
|
11. |
Tsai WC, Tsai WC, Lee HS, et al. Association between osteopontin and EGFR expression with clinicopathological parameters in hepatocellular carcinoma. Chin J Physiol, 2012, 55(6): 412-420.
|
12. |
Deng B, Zhang XF, Zhu XC, et al. Correlation and prognostic value of osteopontin and Bcl-2 in hepatocellular carcinoma patients after curative resection. Oncol Rep, 2013, 30(6): 2795-2803.
|
13. |
Jin Y, Chen JN, Feng ZY, et al. OPN and αvβ3 expression are predictors of disease severity and worse prognosis in hepatocellular carcinoma. PLoS One, 2014, 9(2): e87930.
|
14. |
Ying X, Zhao Y, Wang JL, et al. Serum anti-osteopontin autoantibody as a novel diagnostic and prognostic biomarker in patients with hepatocellular carcinoma. Oncol Rep, 2014, 32(4): 1550-1556.
|
15. |
Chimparlee N, Chuaypen N, Khlaiphuengsin A, et al. Diagnostic and prognostic roles of serum osteopontin and osteopontin promoter polymorphisms in hepatitis B-related hepatocellular carcinoma. Asian Pac J Cancer Prev, 2015, 16(16): 7211-7217.
|
16. |
王代宏, 王伟, 王芳元. 联合检测 VEGF、OPN 对原发性肝癌术后复发转移及预后的意义. 湖北科技学院学报: 医学版, 2015, 29(4): 280-283.
|
17. |
Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol, 2010, 25(9): 603-605.
|
18. |
Oldberg A, Franzén A, Heinegård D. Cloning and sequence analysis of rat bone sialoprotein (osteopontin) cDNA reveals an Arg-Gly-Asp cell-binding sequence. Proc Natl Acad Sci U S A, 1986, 83(23): 8819-8823.
|
19. |
Wu CY, Wu MS, Chiang EP, et al. Elevated plasma osteopontin associated with gastric cancer development, invasion and survival. Gut, 2007, 56(6): 782-789.
|
20. |
Ye QH, Qin LX, Forgues M, et al. Predicting hepatitis B virus-positive metastatic hepatocellular carcinomas using gene expression profiling and supervised machine learning. Nat Med, 2003, 9(4): 416-423.
|
21. |
许英艺, 张雅雅, 卢伟锋, 等. 骨桥蛋白表达与中国人肝癌及其临床病理特征关系的 Meta 分析. 中国循证医学杂志, 2014, 14(12): 1418-1423.
|
22. |
Zhang CH, Xu GL, Jia WD, et al. Prognostic significance of osteopontin in hepatocellular carcinoma: a meta-analysis. Int J Cancer, 2012, 130(11): 2685-2692.
|
23. |
Cheng J, Wang W, Sun C, et al. Meta-analysis of the prognostic and diagnostic significance of serum/plasma osteopontin in hepatocellular carcinoma. J Clin Gastroenterol, 2014, 48(9): 806-814.
|
24. |
Caruso DJ, Carmack AJ, Lokeshwar VB, et al. Osteopontin and interleukin-8 expression is independently associated with prostate cancer recurrence. Clin Cancer Res, 2008, 14(13): 4111-4118.
|
25. |
Park MG, Oh MM, Yoon JH, et al. The value of plasma osteopontin levels as a predictive factor of disease stage and recurrence in patients with bladder urothelial carcinoma: a prospective study. Kaohsiung J Med Sci, 2012, 28(10): 526-530.
|
26. |
Briese J, Cheng S, Ezzat S, et al. Osteopontin (OPN) expression in thyroid carcinoma. Anticancer Res, 2010, 30(5): 1681-1688.
|
27. |
Coppola D, Szabo M, Boulware D, et al. Correlation of osteopontin protein expression and pathological stage across a wide variety of tumor histologies. Clin Cancer Res, 2004, 10(1 Pt 1): 184-190.
|
28. |
Shang S, Plymoth A, Ge S, et al. Identification of osteopontin as a novel marker for early hepatocellular carcinoma. Hepatology, 2012, 55(2): 483-490.
|